A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations

PHASE3RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 28, 2021

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2025

Conditions

NSCLC, Stage IIIAEGF-R Negative Non-Small Cell Lung CancerALK Negative NSCLC

Interventions

DRUG

PD-1 and chemotherapy

Sintilimab+(Squamous)ABX+DDP/CBP, or (non-Squamous)PEM+DDP/CBP

Trial Locations (1)

RECRUITING

Shanghai General Hospital, Shanghai

All Listed Sponsors

lead

Tongji University

OTHER